Alcohol Septal Ablation and Pacemaker Implantation: Results After 5 Years

Alcohol septal ablation is used to treat patients with obstructive hypertrophic cardiomyopathy. A significant complication in this intervention is atrioventricular block requiring pacemaker implantation in 7% to 20% of cases. Current evidence is limited for clinical results at follow-up for these patients.

Ablación septal con alcohol e implante de marcapasos

The aim of this study was to evaluate the results for patients with permanent pacemaker implantation related to high-degree atrioventricular block.

The EURO-ASA multinational registry was used. A total of 1814 patients with 5 years of follow-up were analyzed. Within 30 days after ablation, 9.4% (170 patients) had a pacemaker implanted. 

After, propensity score matching was conducted to homogenize groups, and 278 patients were compared (139 pacemaker arm vs. 139 non-pacemaker arm). There were no long-term differences in terms of functional class and survival. 

However, patients in the pacemaker arm presented a lower long-term left ventricular (LV) outflow tract gradient (p < 0.01), a more pronounced decrease in LV gradient (p < 0.01), lower ejection fraction (= 0.02), and lower rates of reintervention (ablation or surgery) (p = 0.02).

Read also: Prognosis After Pacemaker Implantation in Alcohol Septal Ablation.

In multivariate analysis, older age (p < 0.01) and branch block prior to ablation (p = 0.01) were predictors of all-cause mortality.

Conclusion

Patients with hypertrophic cardiomyopathy treated with alcohol septal ablation had about a 9-% likelihood of pacemaker implantation within 30 days of the procedure. In the long term, patients who underwent pacemaker implantation had lower LV outflow tract gradient, greater steep decline in LV outflow tract gradient, lower ejection fraction, and lower rates of reintervention. However, they had similar survival rates and functional class compared with patients who did not undergo pacemaker implantation.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation.

Reference: Josef Veselka, MD et al J Am Coll Cardiol Intv 2022;15:1910–1917.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...